Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Jun 30, Is This Why Opioids Were Chosen Over Mitraynine as Pain "Killers"?

As many of my readers are aware, opioid Pain drugs tend to quickly build tolerance and a need for increasing doses, leading to addiction.
The mitragynine molecule was studied and apparently rejected for use as a pain reliever, with Smith-Kline-French establishing a patent on a drug made from the herb kratom in 1966. Oddly, for unknown reasons, that patent has never been used.
It just occurred to me that, perhaps Smith-Kline-French preferred to use a drug that was known to cause tolerance over one that didn't, thus increasing the sales of their existing opioid drugs.
I'm just speculating, here, admittedly. But it does seem odd that sufficient research was done to acquire a patent, based on the most prominent alkaloid in kratom -- and yet, that patent was never developed into a drug, even though mitragynine has not been found to cause the deadly "respiratory depression".
The absence of respiratory depression and no tendency to cause hyperalgesia would seem to be big advantages in a painkiller, compared to all opium-derived drugs, if patient health and safety were truly the driving factor in their decision. This adds to the mystery of why kratom is now apparently on the "hit-list" of substances that are targeted to be banned, why marijuana -- a much more potent psychoactive is being increasingly legalized in the USA.
In any case, kratom is still an available pain reliever in 44 states and on the federal level in America. Let's keep it that way!
Here is the article about the increased pain sensitivity caused in some people, called Hyperalgesia, with a list of other herbs and therapies for relieving pain, without opioids.



This post first appeared on Diabetes Symptoms, please read the originial post: here

Share the post

Jun 30, Is This Why Opioids Were Chosen Over Mitraynine as Pain "Killers"?

×

Subscribe to Diabetes Symptoms

Get updates delivered right to your inbox!

Thank you for your subscription

×